Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | New CAR designs

Renier Brentjens • 3 Sep 2020
SOHO 2020
General CAR-T

Renier J. Brentjens, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses novel CAR designs aimed to improve efficacy of CAR T-cell patients, including the development of armoured CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc)

More from Renier Brentjens

Improving CAR development to circumvent the challenges presented by AML
1:44
Improving CAR development to circumvent the challenges presented by AML
Renier Brentjens • 7 Dec 2024
Why does AML present a challenge for the development of successful CAR products?
1:20
Why does AML present a challenge for the development of successful CAR products?
Renier Brentjens • 7 Dec 2024
Developing and testing CD371-targeted CAR T-cells secreting IL-18 for refractory AML
2:29
Developing and testing CD371-targeted CAR T-cells secreting IL-18 for refractory AML
Renier Brentjens • 7 Dec 2024
Challenges in CAR T-cell therapy
3:12
Challenges in CAR T-cell therapy
Renier Brentjens • 4 Sep 2020

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals